CIK 0002020932 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in C9 · fiscal year ends 12/31
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-13 | 6-K | FORM 6-K | 2026-10-13 |
| 2026-10-09 | 4 | PRIMARY DOCUMENT | 2026-10-08 |
| 2026-10-07 | 4 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-10-07 | 4 | PRIMARY DOCUMENT | 2026-10-06 |
| 2026-10-07 | 4 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-10-01 | 6-K | FORM 6-K | 2026-10-01 |
| 2026-09-15 | 4 | OWNERSHIP DOCUMENT | 2026-09-11 |
| 2026-09-15 | 4 | OWNERSHIP DOCUMENT | 2026-09-11 |
| 2026-09-15 | 3 | OWNERSHIP DOCUMENT | 2026-09-11 |
| 2026-09-15 | 3 | OWNERSHIP DOCUMENT | 2026-09-11 |
| 2026-09-14 | 6-K | FORM 6-K | 2026-09-14 |
| 2026-09-11 | 6-K | FORM 6-K | 2026-09-11 |
| 2026-08-10 | 6-K | FORM 6-K | 2026-08-10 |
| 2026-08-06 | 6-K | 6-K | 2026-08-06 |
| 2026-06-23 | 6-K | FORM 6-K | 2026-06-23 |
| 2026-05-27 | 6-K | FORM 6-K | 2026-05-27 |
| 2026-05-15 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-15 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-06 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-24 | 6-K | FORM 6-K | 2026-04-24 |
| 2026-04-23 | 20-F | FORM 20-F | 2025-12-31 |
| 2026-04-16 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-03-18 | 3 | OWNERSHIP DOCUMENT | 2026-03-18 |
| 2026-03-18 | 3 | OWNERSHIP DOCUMENT | 2026-03-18 |
| 2026-03-18 | 3 | OWNERSHIP DOCUMENT | 2026-03-18 |
Forms on file (last 1,000): 3 13, 6-K 11, 4 6, SCHEDULE 13G 5, DRS/A 2, 20-F 1, S-8 1, SCHEDULE 13D 1. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AGMB (0.002 USD), /gw/filings/filings?ticker=AGMB&form=8-K, /gw/filings/facts?ticker=AGMB&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange